Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: Evidence for two distinct mechanisms

Journal of the American Society of Nephrology

Volumn 8, Issue 12, 1997, Pages 1877-1888

  Van Setten, Petra A ^a,b   Van Hinsbergh, Victor W M ^b   Van Den Heuvel, Lambert P W J ^a   Van Der Velden, Thea J A N ^a   Van De Kar, Nicole C A J D E ^a   Krebbers, Raymond J M ^a   Karmali, Mohammed A ^c   Monnens, Leo A H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VEROTOXIN; VEROTOXIN 1; VEROTOXIN 2;

ARTICLE; BETA CHAIN; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE ASSOCIATION; ENDOTOXEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; MESANGIUM CELL; MITOSIS INHIBITION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; TOXICOKINETICS;

EID: 0031421588     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Fong JS, De Chadarevian JP, Kaplan BS: Hemolytic uremic syndrome: Current concepts and management. Pediatr Clin North Am 29: 835-856, 1982
2. Karmali MA, Petric M, Lim C, Fleming DC, Arbus GS, Lior H: The association between idiopathic hemolytic syndrome and infection by verocytotoxin producing Escherichia coli. J Infect Dis 151: 775-782, 1985
3. van de Kar NC, Monnens LA, Karmali MA van Hinsbergh VW: Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 80: 2755-2764, 1992
4. Richardson SE, Karmali MA, Becker LE, Smith CR: The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 19: 1102-1108, 1988
5. Waldherr R, Cuzic S, Noronha IL: Pathology of the human mesangium in situ. Clin Investig 70: 865-874, 1992
6. Shigematsu H, Dikman SH, Churg J, Grishman E, Duffy JL: Mesangial involvement in hemolytic uremic syndrome: A light and electron microscopic study. Am J Pathol 85: 349-362, 1976
7. Rosen S, Schein PS: Hemolytic uremic syndrome in an adult: Light and electron microscopic observations. Am J Clin Pathol 54: 33-46, 1970
8. Morita T, Churg J: Mesangiolysis. Kidney Int 24: 1-9, 1983
9. Sakai T, Kriz W: The structural relationship between mesangial cells and basement membrane of the renal glomerulus. Anat Embryol Berl 176: 373-386, 1987
10. Mene P, Simonson MS, Dunn MJ: Physiology of the mesangial cell. Physiol Rev 69: 1347-1424, 1989
11. Kreisberg JI, Venkatachalam M, Troyer D: Contractile properties of cultured glomerular mesangial cells. Am J Physiol 249: F457-F463, 1985
12. Abboud HE: Resident glomerular cells in glomerular injury: Mesangial cells. Semin Nephrol 11: 304-311, 1991
13. Schlondorff D: The glomerular mesangial cell: An expanding role for a specialized pericyte. FASEB J 1: 272-281, 1987
14. Sterzel RB, Schulze-Lohoff E, Marx M: Cytokines and mesangial cells. Kidney Int 43[Suppl 39]: S26-S31, 1993
15. Striker LJ, Peten EP, Elliot SJ, Doi T, Striker GE: Mesangial cell turnover: Effect of heparin and peptide growth factors. Lab Invest 64: 446-456, 1991
16. Schlondorff D, Mori T: Contributions of mesangial cells to glomerular immune functions. Klin Wochenschr 68: 1138-1144, 1990
17. Obrig TG, Moran TP, Brown JE: The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244: 287-294, 1987
18. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K: Site of action of a Vero toxin (VT2) from Escherichia coli O157: H7 and of Shiga toxin on eukaryotic ribosomes: RNA N-glycosidase activity of the toxins. Eur J Biochem 171: 45-50, 1988
19. O'Brien AD, Holmes RK: Shiga and Shiga-like toxins. Microbiol Rev 51: 206-220, 1987
20. Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R: An endothelial cell growth factor from bovine hypothalamus: Identification and partial characterization. Proc Natl Acad Sci USA 76: 5674-5678, 1979
21. Sterzel RB, Lovett DH, Foellmer HG, Perfetto M, Biemesderfer D, Kashgarian M: Mesangial cell hillocks: Nodular foci of exaggerated growth of cells and matrix in prolonged culture. Am J Pathol 125: 130-140, 1986
22. Muller EW, Kim Y, Michael AF, Vernier RL, van der Hem GK, van der Woude FJ: Explantation of mesangial cell "hillocks": A method for obtaining human mesangial cells in culture. Int J Exp Pathol 73: 9-20, 1992
23. Albelda SM, Muller WA, Buck CA, Newman PJ: Molecular and cellular properties of PECAM-1 (endoCAM/CD31): A novel vascular cell-cell adhesion molecule. J Cell Biol 114: 1059-1068, 1991
24. Van Muijen GN, Ruiter DJ, Warnaar SO: Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest 57: 359-369, 1987
25. Brown PA, Wilson HM, Reid FJ, Booth NA, Simpson JG, Morrison L, Power DA, Haites NE: Urokinase-plasminogen activator is synthesized in vitro by human glomerular epithelial cells but not by mesangial cells. Kidney Int 45: 43-47, 1994
26. van Hinsbergh VW, Vermeer M, Koolwijk P, Grimbergen J, Kooistra T: Genistein reduces tumor necrosis factor alpha-induced plasminogen activator inhibitor-1 transcription but not urokinase expression in human endothelial cells. Blood 84: 2984-2991, 1994
27. Petric M, Karmali MA, Richardson SE, Cheung R: Purification and biological properties of Escherichia coli verocytotoxin-1. FEMS Microbiol Lett 41: 63-68, 1987
28. Head SC, Petric M, Richardson S, Roscoe M, Karmali MA: Purification and characterization of verocytotoxin-2. FEMS Microbiol Lett 51: 211-216, 1988
29. Ramotar K, Boyd B, Tyrrell G, Gariepy J, Lingwood C, Brunton J: Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron. Biochem J 272: 805-811, 1990
30. Salacinski PR, McLean C, Sykes JE, Clement-Jones VV, Lowry PJ: Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). Anal Biochem 117: 136-146, 1981
31. Scatchard G: The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 660-672, 1946
32. Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, De-Grandis S, Karmali M: Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem 262: 8834-8839, 1987
33. Van Setten PA, Monnens LAH, Verstraten RGG, Van den Heuvel LPWJ, Van Hinsbergh VWM: Effects of verocytotoxin-1 on non-adherent human monocytes: Binding characteristics, protein synthesis, and induction of cytokine release. Blood 88: 174-183, 1996
34. van Setten PA van Hinsbergh VWM, van der Velden TJAN, van de Kar NCAJ, Vermeer M, Mahan JD, Assmann KJM, van den Heuvel LPWJ, Monnens LAH: Effects of TNFα on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 51: 1245-1256, 1997
35. Kiarash A, Boyd B, Lingwood CA: Glycosphingolipid receptor function is modified by fatty acid content: Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J Biol Chem 269: 11138-11146, 1994
36. Pellizzari A, Pang H, Lingwood CA: Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 31: 1363-1370, 1992
37. Robinson LA, Hurley RM, Lingwood C, Matsell DG: Escherichia coli verotoxin binding to human paediatric glomerular mesangial cells. Pediatr Nephrol 9: 700-704, 1995
38. Holthofer H, Sainio K, Miettinen A: The glomerular mesangium: Studies of its developmental origin and markers in vivo and in vitro. APMIS 103: 354-366, 1995
39. Holthöfer H, Virtanen I, Pettersson E, Törnroth T, Alfthan O, Linder E, Miettinen A: Lectins as fluorescence microscopic markers for saccharides in the human kidney. Lab Invest 45: 391-399, 1981
40. Hennigar RA, Schulte BA, Spicer SS: Heterogeneous distribution of glycoconjugates in human kidney tubules. Anat Rec 211: 376-390, 1985
41. Laitinen L, Juusela H, Virtanen I: Binding of the blood group-reactive lectins to human adult kidney specimens. Anat Rec 226: 10-17, 1990
42. Howie AJ, Johnson GD: Confocal microscopic and other observations on the distal end of the thick limb of the human loop of Henle. Cell Tissue Res 267: 11-16, 1992
43. Landing BH, Stela MA, Herta NH: Labeled lectin studies of renal tubular dysgenesis and renal tubular atrophy of postnatal renal ischaemia and end-stage kidney disease. Pediatr Pathol 14: 87-99, 1994
44. Tesh VL, Ramegowda B, Samuel JE: Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun 62: 5085-5094, 1994
45. Siegler RL, Edwin SS, Christofferson RD, Mitchell MD: Plasma and urinary cytokines in childhood hemolytic urmemic syndrome [Abstract]. J Am Soc Nephrol 2: 274, 1991
46. Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barratt TM: Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. Kidney Int 42: 951-956, 1992
47. Karpman D, Andreasson A, Thysell H, Kaplan BS, Svanborg C: Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol 9: 694-699, 1995
48. Van de Kar NCAJ, Sauerwein RW, Demacker PNM, Grau GE, Van Hinsbergh VWM, Monnens LAH: Plasma cytokine levels in hemolytic uremic syndrome. Nephron 71: 309-313, 1995
49. Sandvig K van Deurs B: Toxin-induced cell lysis: protection by 3-methyladenine and cycloheximide. Exp Cell Res 200: 253-262, 1992
50. Mangeney M, Lingwood CA, Taga S, Caillou B, Tursz T, Wiels J: Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res 53: 5314-5319, 1993
51. Inward CD, Williams J, Chant I, Crocker J, Milford DV, Rose PE, Taylor CM: Verocytotoxin-1 induces apoptosis in vero cells. J Infect 30: 213-218, 1995
52. Obrig TG, Del-Vecchio PJ, Brown JE, Moran TP, Rowland BM, Judge TK, Rothman SW: Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 56: 2373-2378, 1988
53. Pudymaitis A, Lingwood CA: Susceptibility to verotoxin as a function of the cell cycle. J Cell Physiol 150: 632-639, 1992
54. Sandvig K, Garred O, Prydz K, Kozlov JV, Hansen SH, van Deurs B: Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 358: 510-512, 1992
55. Sandvig K, Ryd M, Garred O, Schweda E, Holm PK, van Deurs B: Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol 126: 53-64, 1994
56. Sandvig K, Garred O, van Helvoort A, van Merr G, van Deurs B: Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells. Mol Biol Cell 7: 1391-1404, 1996
57. Sandvig K, van Deurs B: Endocytosis, intracellular transport and cytotoxic action of shiga toxin and ricin. Physiol Rev 76: 949-966, 1996